Page URL:

Illumina wins NIPT patent case in UK High Court

27 November 2017
Appeared in BioNews 928

The UK Patents Court has ruled that two separate non-invasive prenatal tests (NIPT) infringe patents licensed by the US firm Illumina.

Illumina successfully claimed that the Iona test offered by Premaitha Health was in infringement of five patents, and a gender testing component of Ariosa Diagnostics' Harmony test infringed one patent. Unless the judgment is successfully appealed, both tests may be subject to restrictions limiting their sale on the UK market.

Charles Dadswell, Senior Vice President and General Counsel at Illumina has said: 'We are pleased that the court ruled in our favour. The court's judgment validates the investments Illumina has made, the value of this technology and the significant contributions of the inventors in this field.'

Tests such as Iona and Harmony can detect either the gender of the fetus or chromosomal anomalies by assaying fetal cfDNA in the mother's blood. The techniques are therefore considered to be 'non-invasive' forms of prenatal testing, and offer women an alternative to methods such as amniocentesis and CVS that involve sampling cells from the amniotic fluid and placenta respectively, and are associated with increased risk of miscarriage.

NIPT is available on the NHS for pregnancies considered to be at high risk of trisomies (See BioNews 876). Premaitha's contracts to provide Iona to over 50 NHS hospitals could potentially be affected by the ruling.

The court heard claims involving three different patent families licensed by Illumina: Lo 1, Lo 2&3, and Quake 1&2, named for the scientists on whose work they are based (Professor Dennis Lo of the Chinese University of Hong Kong, and Dr Stephen Quake from Stanford University in California respectively). The patents are owned by the universities, except Lo1 which is held by US firm Sequenom, who offer their own NIPT product: MaterniT21. Illumina claimed that it held exclusive licences for all five.

Both Premaitha and Ariosa claimed that the patents under which they are sued are invalid. However, the court ruled in favour of Illumina, stating that all patents are valid and that the tests involved do, at least in some circumstances, infringe upon them. It is expected that the decision will be appealed by the defendants.

Dr Stephen Little, CEO of Premaitha Health, said: 'We are very disappointed with this ruling and deeply disagree with the interpretation the Judge has given to precise technical language in the patents. The effect of the judgment could potentially limit the access of UK patients to NIPT and, in certain respects, diverges from decisions made in other jurisdictions. We are seeking leave to appeal and continue to believe that the motivation behind these legal actions is competitive rather than technical.'

Illumina Gets Favorable Ruling in UK NIPT Patent Infringement Lawsuit
GenomeWeb |  21 November 2017
Illumina Wins Infringement Suit Against Premaitha Health plc and Ariosa Diagnostics, Inc.
Business Wire |  21 November 2017
Patent court decision
British and Irish Legal Information Institute |  21 November 2017
Prenatal test infringes Illumina patents, rules English High Court
Life Sciences Intellectual Property Review |  22 November 2017
13 September 2021 - by Christina Burke 
Health regulators in five countries are investigating non-invasive prenatal test NIFTY, over data protection concerns....
26 July 2021 - by Tsvetana Stoilova 
Non-invasive prenatal testing to detect chromosomal abnormalities in twin pregnancies is not as accurate as in singleton pregnancies...
1 June 2021 - by Michaela Chen 
A long-running court case over non-invasive prenatal testing patents has been settled...
24 May 2021 - by Dr Hazar Haidar, Professor Vardit Ravitsky and Dr Anne-Marie Laberge 
Non-invasive prenatal testing (NIPT) was first introduced in 2011, when breakthroughs in sequencing technology allowed the analysis of cell-free fetal DNA (cffDNA) in maternal blood to detect genetic abnormalities in the foetus, such as trisomy 21 (Down's syndrome), with greater accuracy than previous screening tests...
29 February 2016 - by Ryan Ross 
The California-based genome-sequencing company Illumina has accused UK rival Oxford Nanopore Technologies of violating its intellectual property rights...
7 December 2015 - by Antony Starza-Allen 
The US federal court of appeals has declined to rehear arguments on the patentability of a prenatal blood test, saying that it remains bound by the Supreme Court to determine the claims as non-patentable...
22 June 2015 - by Ceri Durham 
A US federal appeals court has upheld a ruling that Sequenom's prenatal MaterniT21 test is not sufficiently 'inventive' to be patentable....
20 October 2014 - by Sean Byrne 
Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce...
26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.